EClinicalMedicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-12-23 12598275m58暂无昵称来自陕西省

2022年中科院分区医学3区😂😂

122 0

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-10-11 Oncosurgeon-J

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！

200 0

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-02-28 feo93

每次required review completed 后要多久给反馈？

400 0

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2019-11-28 lovetcm

审稿速度:2.0 | 投稿命中率:75.0
经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦

618 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-04-01 ms3000000001679338

偏重的研究方向：肿瘤
经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能

512 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-03-24 1881f0fc47m

有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确

497 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-03-15 医者仁者

偏重的研究方向：外科;肿瘤;糖尿病
经验分享：现在稿源还少，推荐

341 0

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-01-26 ms7524559905309751

投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：预期5-6分左右

361 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-03-09 dangjunsy

为什么最近的很多帖子都被删掉了？

353 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2107205, encodeId=bab0210e205d4, content=2022年中科院分区医学3区😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c322577271, createdName=12598275m58暂无昵称, createdTime=Fri Dec 23 21:23:42 CST 2022, time=2022-12-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2093254, encodeId=945b2093254b5, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：分享eClinicalMedicine投稿经历，审稿效率较高，编辑非常友好且细致，祝大家投稿顺利！ 4.29 submitted 5.4 with editor 5.9 under review 期间required reviews completed与under review每1-2周交替变换日期 6.17 revise（editor, Vincenzo Giacco教授给了4周时间）申请延期至7.27日 3个审稿人，审稿意见3616字...第一个reviewer共17条意见，第二个reviewer共21条意见，第三个reviewer是个统计师，11条统计方面的问题 7.26 R1 resubmitted 7.27 with editor 7.29 under review 期间required reviews completed与under review交替变换日期 8.26 邮件催稿 9.5 编辑回信，刚度假回来，后面会加急稿件 9.16 revise（editor给了2周时间）之前的3个审稿人，第一个reviewer追问了1个问题，第二个reviewer追问了12个问题，第三个reviewer追问了2条统计方面的问题 9.20 R2 resubmitted 9.21 with editor 9.22 under review 10.6 revise（editor给了10天时间）之前的3个审稿人，第一个reviewer让修改一处细节，第二个reviewer同意发表，第三个reviewer让修改一处细节 10.6 R3 resubmitted 10.6 with editor 10.6 under review 10.10 accept 编辑周六周日都是休息不上班的，也就是不会有任何邮件，另可能会有年假，话说英国的福利就是好哇，最后，祝杂志越来越好，大家文章顺利发表！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Tue Oct 11 23:33:53 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197897, encodeId=6f9d119e897f3, content=每次required review completed 后要多久给反馈？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be8d1612246, createdName=feo93, createdTime=Mon Feb 28 06:01:22 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=618, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207939, encodeId=a4ec120e9398f, content=偏重的研究方向：肿瘤 经验分享：已接受，学之策及时IF15，吓到我了感觉不太可能, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=512, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff06569374, createdName=ms3000000001679338, createdTime=Fri Apr 01 20:50:03 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202948, encodeId=9f2d1202948ff, content=偏重的研究方向：外科;肿瘤;糖尿病 经验分享：现在稿源还少，推荐, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Tue Mar 15 23:51:48 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188387, encodeId=2f87118838e2f, content=投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：预期5-6分左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/lOv6uzmxsoL3HjKFWWGraianvia19uZCHERLT0Rlbr7ibHPib5yooBq8MB5lO3asBfmThneDqPJVvdBMOpuA9wufvA/0, createdBy=15b32160705, createdName=ms7524559905309751, createdTime=Wed Jan 26 19:37:03 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=353, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198986, encodeId=72a41198986ec, content=还可以, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb355507716, createdName=Relivenus, createdTime=Thu Mar 03 10:00:33 CST 2022, time=2022-03-03, status=1, ipAttribution=)]

2022-03-03 Relivenus

还可以

127 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务